CD146在胶质瘤干细胞中高表达并作为细胞周期调节因子
该研究在常规培养的胶质瘤细胞与肿瘤球中过表达或敲低CD146,用流式细胞术结合CD133与A2B5分析细胞周期分布,并对胶质瘤组织行免疫组化。结果显示表达CD133的胶质瘤干细胞多数同时为CD146阳性,敲低CD146显著抑制干细胞生长,CD146与CD133双阳性细胞多处于G2/M期,且CD146在WHO III、IV级胶质瘤中表达上调并与CD133正相关。
要点
- CD146主要表达于增殖中的胶质瘤干细胞,与CD133共表达。
- 敲低CD146可显著抑制胶质瘤干细胞生长。
- CD146在WHO III、IV级胶质瘤中表达上调,与CD133正相关。
核心结论
- CD146主要表达于分裂中的胶质瘤干细胞,可能成为清除胶质瘤干细胞的潜在靶点。
研究设计与样本
- 在常规培养的胶质瘤细胞和肿瘤球中过表达或敲低CD146。
- 用流式细胞术结合干细胞标志物CD133和胶质前体标志物A2B5分析细胞周期分布。
- 对胶质瘤组织行免疫组化检测CD146表达。
主要发现
- 表达CD133的胶质瘤干细胞大多数也为CD146阳性。
- 在胶质瘤干细胞中敲低CD146显著损害细胞生长。
- CD146与CD133双阳性细胞多数处于G2/M期。
- 在亲本胶质瘤细胞中异位表达CD146使多数分化细胞阻滞于G0/G1期。
- 在胶质瘤干细胞中异位表达CD146使G2/M期CD133阳性细胞数量增加,敲低CD146则减少G2/M期CD133阳性细胞。
关键数值与推荐
- CD146表达在WHO III级和IV级胶质瘤中显著上调,且与CD133表达呈正相关。
- CD146与CD133双阳性细胞多数位于G2/M期。
临床怎么用
- 提示CD146可作为识别增殖性胶质瘤干细胞的标志物并作为潜在治疗靶点,但尚需进一步验证。
局限性
- 原文摘要未报告样本量、具体统计数值及临床随访信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: CD146 is highly expressed in various malignant tumors and contributes to their malignancy phenotype, which involves metastatic and tumorigenic activity. However, studies on the expression and function of CD146 in brain tumors are limited. METHODS: We over-expressed or knocked-down CD146 in both conventionally cultured glioma cells and tumor spheres (TS). The distribution of glioma cells and their stem cells in different cell cycle phases was analyzed by flow cytometry using the stem cell marker CD133 and the glial precursor marker A2B5. CD146 expression was immunohistochemically examined in glioma tissues. RESULTS: The majority of glioma stem cells (GSCs) expressing CD133 were also CD146-positive. CD146 knockdown in GSCs significantly compromised cell growth. Cell cycle analysis revealed that most of the CD146 and CD133 double-positive cells were in the G2/M phase. Ectopic expression of CD146 in parental glioma cells resulted in cell cycle arrest of most differentiated cells in G0/G1 phase. In contrast, ectopic expression of CD146 in GSCs resulted in an increase in the number of CD133-positive cells in the G2/M phase. Furthermore, CD146 knockdown reduced the number of CD133-positive cells in the G2/M phase, which was consistent with effects of cell growth inhibition. Immunohistochemical analysis revealed that CD146 expression was significantly upregulated in World Health Organization (WHO) Grade III and IV glioma and positively correlated with CD133 expression. CONCLUSIONS: CD146 is mainly expressed in dividing GSCs and may be a potential target for eradicating glioma stem cells.
引用
- Yawata T, Higashi Y, Kawanishi Y, et al. CD146 is highly expressed in glioma stem cells and acts as a cell cycle regulator. J Neurooncol. 2019. PMID: 31147892. doi:10.1007/s11060-019-03200-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。